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Abstract 
The unique physical-chemical properties of Nanoparticles (NPs) make them suitable for many 
biomedical applications (drug delivery, imaging, cell tacking) (Yildirimer et al, 2011). However, the design 
of nanoparticle-based platforms for nanomedicine is extremely challenging and must overcome a 
number of physiologically constraints, including the Mononuclear Phagocyte System (MPS) (Dawidczyk 
et al, 2014). 
The aim of this study was to assess the role of MPS in the biodistribution and accumulation of metallic 
NPs [iron-oxide NPS and silver NPs (AgNPs)] after single intravenous administration in mice. 24 hours 
after the treatment mice were sacrificed and underwent complete necropsy. Liver, kidney, spleen and 
lung were collected, stained with hematoxylin and eosin (HE), Perls stain (for iron-oxide NPs) or 
autometallography (for AgNPs), and evaluated under a light microscope. Immunostaining for Iba-1 (pan 
macrophage marker) was applied to localize the NPs aggregates within MPS cells. 
Histologically, in all treated mice, intracytoplasmic brown granular material (consistent with iron or 
silver pigment, as confirmed by Perls iron stain and autometallography) was found in stained sections 
of the liver (within Kupffer cells), spleen (MPS of marginal zone and red pulp) and lung (MPS within 
alveolar septa). Iron/silver deposits were mainly found in the cytoplasm of MPS cells (Iba1 
immunostaining), indicating that most of injected particles were removed from blood circulation by 
phagocytic cells. These findings indicate that MPS greatly influence NPs biodistribution. For this reason, 
strategies able to increase bioavailability of NPs by minimizing MPS-mediated clearance are needed. 
Moreover, the potential toxic effects due to the persistence of NPs in MPS should be further 
investigated. 
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